Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886212 | 1.00 | KCNH2 (0.62) | KCNH2SCN3AKDM4EALDH1A1GAA | |
| SCHEMBL5886076 | 1.00 | KCNH2 (0.62) | KCNH2SCN3AKDM4EALDH1A1GAA | |
| SCHEMBL4089338 | 0.90 | KCNH2 (0.52) | KCNH2SCN3AKDM4EALDH1A1GAA | |
| SCHEMBL28308810 | 0.88 | KCNH2 (0.64) | KCNH2SCN3AKDM4EALDH1A1GAA | |
| SCHEMBL197791 | 0.84 | KCNH2 (0.56) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL135105 | 0.84 | KCNH2 (0.56) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL8513273 | 0.84 | KCNH2 (0.56) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL197425 | 0.84 | KCNH2 (0.56) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL135106 | 0.84 | KCNH2 (0.56) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL1226045 | 0.84 | KCNH2 (0.56) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023197984-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | 成都海博为药业有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-116891488-A | Condensed-cyclic compound, pharmaceutical composition containing condensed-cyclic compound and application of condensed-cyclic compound | 成都海博为药业有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-6995182-B2 | 1-sulfonyl pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1299383-B1 | SULFONYL-PYRROLIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-01-12 | — | — | EP | disclosed |
| US-20030212066-A1 | 1-Sulfonyl pyrrolidine derivatives | MUTEL VINCENT (FR) | 2003-11-13 | — | — | US | disclosed |
| US-6589978-B2 | Therapy for nervous system disorders | HOFFMAN-LA ROCHE INC. | 2003-07-08 | — | — | US | disclosed |
| EP-1299383-A1 | SULFONYL-PYRROLIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| US-20020019424-A1 | 1-sulfonyl pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | US | disclosed |
| WO-2002002554-A1 | SULFONYL-PYRROLIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212066-A1 | 1-Sulfonyl pyrrolidine derivatives | GRM1, GRM2, GRIN1 | KCNH2 571/4885SCN3A 393/4885KDM4E 2664/4885 |
| US-20020019424-A1 | 1-sulfonyl pyrrolidine derivatives | GRM1, GRM2, GRIN1 | KCNH2 571/4885SCN3A 393/4885KDM4E 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.